Intensity Therapeutics, Inc. INTS 深 滬
等待開盤 11-01 09:30:00 美东时间
0.7302
-0.590
-44.68%
華盛通- 最 高1.15
- 今 開0.9856
- 成交量 1.96亿股
- 最 低 0.70
- 昨 收 1.32
- 總市值 3582.03万
- 52周最高 3.3985
- 市盈率 靜 --
- 換手率 400.51%
- 52周最低 0.1853
- 委 比 73.61%
- 總股本 4905.55万
- 歷史最高 11.44
- 量 比 0.68
- 振 幅 34.09%
- 歷史最低 0.1853
- 每 手 1
- 風險率 1.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Intensity Therapeutics Enters Securities Purchase Agreement
Intensity Therapeutics, Inc. ( ($INTS) ) has provided an announcement. On Octob...
今天 05:18
Catalyst Watch - Tesla holder vote on Musk pay; AMD, Palantir earnings
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - November ...
今天 03:11
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Alphatec Holdings (NASDAQ:ATEC) shares rose 21.7% to $19.88 during Fri...
10-31 20:10
Why Beneficient (BENF) Shares Soared More Than 46% Overnight?
Beneficient shares surged overnight after the company said it regained compliance with two Nasdaq listing requirements.
10-31 15:52
癌症候选药物1/2期临床数据积极，Intensity Therapeutics(INTS.US)股价暴涨395%
生物制药公司Intensity Therapeutics，周四公布其转移性或难治性癌症候选药物INT230-6的1/2期临床试验结果后，股价收盘暴涨近395%。
10-31 08:09
Intensity Therapeutics shares are trading higher after the company announced the publication of its INT230-6 clinical results in eBioMedicine.
Intensity Therapeutics shares are trading higher after the company announced th...
10-30 21:07
Intensity Therapeutics Pauses Enrollment in INVINCIBLE-4 Study
An update from Intensity Therapeutics, Inc. ( ($INTS) ) is now available. On Se...
09-11 04:38
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares increased by 239.0% to ...
09-10 20:11
Intensity Therapeutics Reports Early Radiological And Pathological Results With INT230 6 Demonstrating High Drug Absorption Tumor Necrosis And Evidence Of Immune Activation
A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patient receives two doses of INT230-6 eight days apart, followed by the standard of care
09-10 19:49
Benchmark Maintains Speculative Buy on Intensity Therapeutics, Lowers Price Target to $1.5
Benchmark analyst Robert Wasserman maintains Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and lowers the price target from $4 to $1.5.
08-20 20:59
